{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:13:51Z","timestamp":1791224031158,"version":"4.1.0"},"reference-count":83,"publisher":"Bentham Science Publishers Ltd.","issue":"18","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,6,3]]},"abstract":"<jats:sec><jats:title\/><jats:p>FTY720 (Fingolimod) is a known sphingosine-1-phosphate (S1P) receptor agonist that exerts strong anti-inflammatory effects and was approved as the first oral drug for the treatment of multiple sclerosis by the US Food and Drug Administration (FDA) in 2010. FTY720 is mainly associated with unique functional \u201cantagonist\u201d and \u201cagonist\u201d mechanisms. The functional antagonistic mechanism is mediated by the transient down-regulation and degradation of S1P receptors on lymphocytes, which prevents lymphocytes from entering the blood stream from the lymph node. This subsequently results in the development of lymphopenia and reduces lymphocytic inflammation. Functional agonistic mechanisms are executed through S1P receptors expressed on the surface of various cells including neurons, astrocytes, microglia, and blood vessel endothelial cells. These functions might play important roles in regulating anti-apoptotic systems, modulating brain immune and phagocytic activities, preserving the Blood-Brain-Barrier (BBB), and the proliferation of neural precursor cells. Recently, FTY720 have shown receptor-independent effects, including intracellular target bindings and epigenetic modulations. Many researchers have recognized the positive effects of FTY720 and launched basic and clinical experiments to test the use of this agent against stroke. Although the mechanism of FTY720 has not been fully elucidated, its efficacy against cerebral stroke is becoming clear, not only in animal models, but also in ischemic stroke patients through clinical trials. In this article, we review the data obtained from laboratory findings and preliminary clinical trials using FTY720 for stroke treatment.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867326666190308133732","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T14:53:20Z","timestamp":1575298400000},"page":"2979-2993","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment"],"prefix":"10.2174","volume":"27","author":[{"given":"Zifeng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Kawabori","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiro","family":"Houkin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.7164\/antibiotics.47.208","volume":"47","author":"Fujita T.","year":"1994","unstructured":"Fujita T.; Inoue K.; Yamamoto S.; Ikumoto T.; Sasaki S.; Toyama R.; Chiba K.; Hoshino Y.; Okumoto T.; Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo) 1994,47(2),208-215","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.intimp.2010.10.005","volume":"11","author":"Chiba K.","year":"2011","unstructured":"Chiba K.; Kataoka H.; Seki N.; Shimano K.; Koyama M.; Fukunari A.; Sugahara K.; Sugita T.; Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-\u03b2 in mouse experimental autoimmune encephalomyelitis. Int Immunopharmacol 2011,11(3),366-372","journal-title":"Int Immunopharmacol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/jnr.21586","volume":"86","author":"Singh I.N.","year":"2008","unstructured":"Singh I.N.; Hall E.D.; Multifaceted roles of sphingosine-1-phosphate: how does this bioactive sphingolipid fit with acute neurological injury? J Neurosci Res 2008,86(7),1419-1433","journal-title":"J Neurosci Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4330\/wjc.v5.i4.75","volume":"5","author":"Kawabori M.","year":"2013","unstructured":"Kawabori M.; Kacimi R.; Karliner J.S.; Yenari M.A.; Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets. World J Cardiol 2013,5(4),75-86","journal-title":"World J Cardiol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1172\/JCI57144","volume":"121","author":"Bikman B.T.","year":"2011","unstructured":"Bikman B.T.; Summers S.A.; Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest 2011,121(11),4222-4230","journal-title":"J Clin Invest"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"12275","DOI":"10.1073\/pnas.92.26.12275","volume":"92","year":"2001","unstructured":"aChang, Y.; Abe, A.; Shayman, J.A. Ceramide formation during heat shock: A potential mediator of alpha B-crystallin transcription. Proc Natl Acad Sci USA 2001,92(26),12275-12279","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"15823","DOI":"10.1016\/S0021-9258(18)55472-7","volume":"265","author":"Okazaki T.","year":"1990","unstructured":"Okazaki T.; Bielawska A.; Bell R.M.; Hannun Y.A.; Role of ceramide as a lipid mediator of 1 alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J Biol Chem 1990,265(26),15823-15831","journal-title":"J Biol Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"14788","DOI":"10.1073\/pnas.0406536101","volume":"101","author":"Suzuki E.","year":"2004","unstructured":"Suzuki E.; Handa K.; Toledo M.S.; Hakomori S.; Sphingosine-dependent apoptosis: a unified concept based on multiple mechanisms operating in concert. Proc Natl Acad Sci USA 2004,101(41),14788-14793","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/jbt.20227","volume":"22","author":"Vessey D.A.","year":"2008","unstructured":"Vessey D.A.; Li L.; Kelley M.; Zhang J.; Karliner J.S.; Sphingosine can pre- and post-condition heart and utilizes a different mechanism from sphingosine 1-phosphate. J Biochem Mol Toxicol 2008,22(2),113-118","journal-title":"J Biochem Mol Toxicol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1124\/pr.54.2.265","volume":"54","author":"Chun J.","year":"2002","unstructured":"Chun J.; Goetzl E.J.; Hla T.; Igarashi Y.; Lynch K.R.; Moolenaar W.; Pyne S.; Tigyi G.; International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 2002,54(2),265-269","journal-title":"Pharmacol Rev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1042\/bj3520809","volume":"352","author":"Murata N.","year":"2000","unstructured":"Murata N.; Sato K.; Kon J.; Tomura H.; Yanagita M.; Kuwabara A.; Ui M.; Okajima F.; Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 2000,352(Pt 3),809-815","journal-title":"Biochem J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1126\/science.1139221","volume":"316","author":"Pappu R.","year":"2007","unstructured":"Pappu R.; Schwab S.R.; Cornelissen I.; Pereira J.P.; Regard J.B.; Xu Y.; Camerer E.; Zheng Y.W.; Huang Y.; Cyster J.G.; Coughlin S.R.; Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007,316(5822),295-298","journal-title":"Science"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1126\/science.1113640","volume":"309","author":"Schwab S.R.","year":"2005","unstructured":"Schwab S.R.; Pereira J.P.; Matloubian M.; Xu Y.; Huang Y.; Cyster J.G.; Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005,309(5741),1735-1739","journal-title":"Science"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"46832","DOI":"10.1074\/jbc.M306577200","volume":"278","author":"Igarashi N.","year":"2003","unstructured":"Igarashi N.; Okada T.; Hayashi S.; Fujita T.; Jahangeer S.; Nakamura S.; Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem 2003,278(47),46832-46839","journal-title":"J Biol Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.bbrc.2003.09.194","volume":"311","author":"Inagaki Y.","year":"2003","unstructured":"Inagaki Y.; Li P.Y.; Wada A.; Mitsutake S.; Igarashi Y.; Identification of functional nuclear export sequences in human sphingosine kinase 1. Biochem Biophys Res Commun 2003,311(1),168-173","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"23722","DOI":"10.1074\/jbc.273.37.23722","volume":"273","author":"Kohama T.","year":"1998","unstructured":"Kohama T.; Olivera A.; Edsall L.; Nagiec M.M.; Dickson R.; Spiegel S.; Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem 1998,273(37),23722-23728","journal-title":"J Biol Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0014-5793(03)01168-2","volume":"554","author":"Paugh S.W.","year":"2003","unstructured":"Paugh S.W.; Payne S.G.; Barbour S.E.; Milstien S.; Spiegel S.; The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 2003,554(1-2),189-193","journal-title":"FEBS Lett"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1074\/jbc.M110.171116","volume":"286","author":"Hisano Y.","year":"2011","unstructured":"Hisano Y.; Kobayashi N.; Kawahara A.; Yamaguchi A.; Nishi T.; The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. J Biol Chem 2011,286(3),1758-1766","journal-title":"J Biol Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.11.001","volume":"185","author":"Huwiler A.","year":"2018","unstructured":"Huwiler A.; Zangemeister-Wittke U.; The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives. Pharmacol Ther 2018,185,34-49","journal-title":"Pharmacol Ther"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1182\/blood-2004-02-0452","volume":"105","author":"Limaye V.","year":"2005","unstructured":"Limaye V.; Li X.; Hahn C.; Xia P.; Berndt M.C.; Vadas M.A.; Gamble J.R.; Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K\/Akt and regulation of Bcl-2 family members. Blood 2005,105(8),3169-3177","journal-title":"Blood"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1046\/j.0953-816x.2001.01585.x","volume":"13","author":"P\u00e9bay A.","year":"2001","unstructured":"P\u00e9bay A.; Toutant M.; Pr\u00e9mont J.; Calvo C.F.; Venance L.; Cordier J.; Glowinski J.; Tenc\u00e9 M.; Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur J Neurosci 2001,13(12),2067-2076","journal-title":"Eur J Neurosci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.neulet.2009.12.070","volume":"470","author":"Agudo-L\u00f3pez A.","year":"2010","unstructured":"Agudo-L\u00f3pez A.; Miguel B.G.; Fern\u00e1ndez I.; Mart\u00ednez A.M.; Involvement of mitochondria on neuroprotective effect of sphingosine-1-phosphate in cell death in an in vitro model of brain ischemia. Neurosci Lett 2010,470(2),130-133","journal-title":"Neurosci Lett"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.160.10.5037","volume":"160","author":"Chiba K.","year":"1998","unstructured":"Chiba K.; Yanagawa Y.; Masubuchi Y.; Kataoka H.; Kawaguchi T.; Ohtsuki M.; Hoshino Y.; FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998,160(10),5037-5044","journal-title":"J Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1161\/STROKEAHA.116.015371","volume":"47","author":"Brait V.H.","year":"2016","unstructured":"Brait V.H.; Tarras\u00f3n G.; Gavald\u00e0 A.; Godessart N.; Planas A.M.; Selective sphingosine 1-phosphate receptor 1 agonist is protective against ischemia\/reperfusion in mice. Stroke 2016,47(12),3053-3056","journal-title":"Stroke"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2040-7378-3-2","volume":"3","author":"Pfeilschifter W.","year":"2011","unstructured":"Pfeilschifter W.; Czech-Zechmeister B.; Sujak M.; Foerch C.; Wichelhaus T.A.; Pfeilschifter J.; Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice. Exp Transl Stroke Med 2011,3,2","journal-title":"Exp Transl Stroke Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3389\/fimmu.2018.01696","volume":"9","author":"Herz J.","year":"2018","unstructured":"Herz J.; K\u00f6ster C.; Crasm\u00f6ller M.; Abberger H.; Hansen W.; Felderhoff-M\u00fcser U.; Bendix I.; Peripheral T cell depletion by FTY720 exacerbates hypoxic-ischemic brain injury in neonatal mice. Front Immunol 2018,9,1696","journal-title":"Front Immunol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2012-04-426734","volume":"121","author":"Kleinschnitz C.","year":"2013","unstructured":"Kleinschnitz C.; Kraft P.; Dreykluft A.; Hagedorn I.; G\u00f6bel K.; Schuhmann M.K.; Langhauser F.; Helluy X.; Schwarz T.; Bittner S.; Mayer C.T.; Brede M.; Varallyay C.; Pham M.; Bendszus M.; Jakob P.; Magnus T.; Meuth S.G.; Iwakura Y.; Zernecke A.; Sparwasser T.; Nieswandt B.; Stoll G.; Wiendl H.; Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood 2013,121(4),679-691","journal-title":"Blood"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1161\/STROKEAHA.113.002880","volume":"44","author":"Kraft P.","year":"2013","unstructured":"Kraft P.; G\u00f6b E.; Schuhmann M.K.; G\u00f6bel K.; Deppermann C.; Thielmann I.; Herrmann A.M.; Lorenz K.; Brede M.; Stoll G.; Meuth S.G.; Nieswandt B.; Pfeilschifter W.; Kleinschnitz C.; FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke 2013,44(11),3202-3210","journal-title":"Stroke"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/ana.22186","volume":"69","author":"Wei Y.","year":"2011","unstructured":"Wei Y.; Yemisci M.; Kim H.H.; Yung L.M.; Shin H.K.; Hwang S.K.; Guo S.; Qin T.; Alsharif N.; Brinkmann V.; Liao J.K.; Lo E.H.; Waeber C.; Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol 2011,69(1),119-129","journal-title":"Ann Neurol"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133392","volume":"10","author":"Spampinato S.F.","year":"2015","unstructured":"Spampinato S.F.; Obermeier B.; Cotleur A.; Love A.; Takeshita Y.; Sano Y.; Kanda T.; Ransohoff R.M.; Sphingosine 1 phosphate at the blood brain barrier: Can the modulation of S1P receptor 1 influence the response of endothelial cells and astrocytes to inflammatory Stimuli? PLoS One 2015,10(7)","journal-title":"PLoS One"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.308","volume":"5","author":"Zhao Z.","year":"2017","unstructured":"Zhao Z.; Wang J.; Huo Z.; Wang Z.; Mei Q.; FTY720 elevates smooth muscle contraction of aorta and blood pressure in rats via ERK activation. Pharmacol Res Perspect 2017,5(3)","journal-title":"Pharmacol Res Perspect"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nri3265","volume":"12","author":"Ransohoff R.M.","year":"2012","unstructured":"Ransohoff R.M.; Engelhardt B.; The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 2012,12(9),623-635","journal-title":"Nat Rev Immunol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/156720208783565645","volume":"5","author":"Kaur C.","year":"2008","unstructured":"Kaur C.; Ling E.A.; Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res 2008,5(1),71-81","journal-title":"Curr Neurovasc Res"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/629782","volume":"2013","year":"2013","unstructured":"aLan, R.; Xiang, J.; Wang, G.H.; Li, W.W.; Zhang, W.; Xu, L.L.; Cai, D.F. Xiao-Xu-Ming decoction protects against blood-brain barrier disruption and neurological injury induced by cerebral is-chemia and reperfusion in rats. Evid Based Complement Alternat Med 2013,2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1161\/01.STR.0000016405.06729.83","volume":"33","author":"Brown R.C.","year":"2002","unstructured":"Brown R.C.; Davis T.P.; Calcium modulation of adherens and tight junction function: a potential mechanism for blood-brain barrier disruption after stroke. Stroke 2002,33(6),1706-1711","journal-title":"Stroke"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrn1824","volume":"7","author":"Abbott N.J.","year":"2006","unstructured":"Abbott N.J.; R\u00f6nnb\u00e4ck L.; Hansson E.; Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006,7(1),41-53","journal-title":"Nat Rev Neurosci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1124\/pr.57.2.4","volume":"57","author":"Hawkins B.T.","year":"2005","unstructured":"Hawkins B.T.; Davis T.P.; The blood-brain barrier\/neurovascular unit in health and disease. Pharmacol Rev 2005,57(2),173-185","journal-title":"Pharmacol Rev"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1124\/jpet.109.153544","volume":"331","author":"Camp S.M.","year":"2009","unstructured":"Camp S.M.; Bittman R.; Chiang E.T.; Moreno-Vinasco L.; Mirzapoiazova T.; Sammani S.; Lu X.; Sun C.; Harbeck M.; Roe M.; Natarajan V.; Garcia J.G.; Dudek S.M.; Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro. J Pharmacol Exp Ther 2009,331(1),54-64","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.molmed.2015.03.006","volume":"21","author":"Prager B.","year":"2015","unstructured":"Prager B.; Spampinato S.F.; Ransohoff R.M.; Sphingosine 1-phosphate signaling at the blood-brain barrier. Trends Mol Med 2015,21(6),354-363","journal-title":"Trends Mol Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1600-6143.2004.00476.x","volume":"4","author":"Brinkmann V.","year":"2004","unstructured":"Brinkmann V.; Cyster J.G.; Hla T.; FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004,4(7),1019-1025","journal-title":"Am J Transplant"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"29190","DOI":"10.1074\/jbc.M604310200","volume":"281","author":"Lee J.F.","year":"2006","unstructured":"Lee J.F.; Zeng Q.; Ozaki H.; Wang L.; Hand A.R.; Hla T.; Wang E.; Lee M.J.; Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J Biol Chem 2006,281(39),29190-29200","journal-title":"J Biol Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1073\/pnas.1618659114","volume":"114","author":"Yanagida K.","year":"2017","unstructured":"Yanagida K.; Liu C.H.; Faraco G.; Galvani S.; Smith H.K.; Burg N.; Anrather J.; Sanchez T.; Iadecola C.; Hla T.; Size-selective opening of the blood-brain barrier by targeting endothelial sphingosine 1-phosphate receptor 1. Proc Natl Acad Sci USA 2017,114(17),4531-4536","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/j.1471-4159.2006.04295.x","volume":"100","author":"Pilorget A.","year":"2007","unstructured":"Pilorget A.; Demeule M.; Barakat S.; Marvaldi J.; Luis J.; B\u00e9liveau R.; Modulation of P-glycoprotein function by sphingosine kinase-1 in brain endothelial cells. J Neurochem 2007,100(5),1203-1210","journal-title":"J Neurochem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/j.1476-5381.2009.00451.x","volume":"158","author":"Brinkmann V.","year":"2009","unstructured":"Brinkmann V.; FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009,158(5),1173-1182","journal-title":"Br J Pharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s12975-013-0260-7","volume":"4","author":"Hasegawa Y.","year":"2013","unstructured":"Hasegawa Y.; Suzuki H.; Altay O.; Rolland W.; Zhang J.H.; Role of the sphingosine metabolism pathway on neurons against experimental cerebral ischemia in rats. Transl Stroke Res 2013,4(5),524-532","journal-title":"Transl Stroke Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"344","DOI":"10.7150\/ijms.8140","volume":"11","author":"Huang L.","year":"2014","unstructured":"Huang L.; Wu Z.B.; Zhuge Q.; Zheng W.; Shao B.; Wang B.; Sun F.; Jin K.; Glial scar formation occurs in the human brain after ischemic stroke. Int J Med Sci 2014,11(4),344-348","journal-title":"Int J Med Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","volume":"23","author":"Sospedra M.","year":"2005","unstructured":"Sospedra M.; Martin R.; Immunology of multiple sclerosis. Annu Rev Immunol 2005,23,683-747","journal-title":"Annu Rev Immunol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/j.1471-4159.2007.04629.x","volume":"102","author":"Mullershausen F.","year":"2007","unstructured":"Mullershausen F.; Craveiro L.M.; Shin Y.; Cortes-Cros M.; Bassilana F.; Osinde M.; Wishart W.L.; Guerini D.; Thallmair M.; Schwab M.E.; Sivasankaran R.; Seuwen K.; Dev K.K.; Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem 2007,102(4),1151-1161","journal-title":"J Neurochem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/glia.10180","volume":"41","author":"Yamagata K.","year":"2003","unstructured":"Yamagata K.; Tagami M.; Torii Y.; Takenaga F.; Tsumagari S.; Itoh S.; Yamori Y.; Nara Y.; Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia 2003,41(2),199-206","journal-title":"Glia"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1073\/pnas.1014154108","volume":"108","author":"Choi J.W.","year":"2011","unstructured":"Choi J.W.; Gardell S.E.; Herr D.R.; Rivera R.; Lee C.W.; Noguchi K.; Teo S.T.; Yung Y.C.; Lu M.; Kennedy G.; Chun J.; FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 2011,108(2),751-756","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2010.03.004","volume":"32","author":"Kang Z.","year":"2010","unstructured":"Kang Z.; Altuntas C.Z.; Gulen M.F.; Liu C.; Giltiay N.; Qin H.; Liu L.; Qian W.; Ransohoff R.M.; Bergmann C.; Stohlman S.; Tuohy V.K.; Li X.; Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 2010,32(3),414-425","journal-title":"Immunity"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"Brinkmann V.","year":"2010","unstructured":"Brinkmann V.; Billich A.; Baumruker T.; Heining P.; Schmouder R.; Francis G.; Aradhye S.; Burtin P.; Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010,9(11),883-897","journal-title":"Nat Rev Drug Discov"},{"key":"ref=53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070124","volume":"8","author":"Brunkhorst R.","year":"2013","unstructured":"Brunkhorst R.; Kanaan N.; Koch A.; Ferreir\u00f3s N.; Mirceska A.; Zeiner P.; Mittelbronn M.; Derouiche A.; Steinmetz H.; Foerch C.; Pfeilschifter J.; Pfeilschifter W.; FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke. PLoS One 2013,8(7)","journal-title":"PLoS One"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3389\/fneur.2017.00467","volume":"8","author":"Mizuma A.","year":"2017","unstructured":"Mizuma A.; Yenari M.A.; Anti-inflammatory targets for the treatment of reperfusion injury in stroke. Front Neurol 2017,8,467","journal-title":"Front Neurol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1634\/stemcells.2006-0223","volume":"25","author":"Kimura A.","year":"2007","unstructured":"Kimura A.; Ohmori T.; Ohkawa R.; Madoiwa S.; Mimuro J.; Murakami T.; Kobayashi E.; Hoshino Y.; Yatomi Y.; Sakata Y.; Essential roles of sphingosine 1-phosphate\/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 2007,25(1),115-124","journal-title":"Stem Cells"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2017.03.034","volume":"119","author":"Das A.","year":"2017","unstructured":"Das A.; Arifuzzaman S.; Kim S.H.; Lee Y.S.; Jung K.H.; Chai Y.G.; FTY720 (fingolimod) regulates key target genes essential for inflammation in microglial cells as defined by high-resolution mRNA sequencing. Neuropharmacology 2017,119,1-14","journal-title":"Neuropharmacology"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1161\/STROKEAHA.117.018505","volume":"48","author":"Qin C.","year":"2017","unstructured":"Qin C.; Fan W.H.; Liu Q.; Shang K.; Murugan M.; Wu L.J.; Wang W.; Tian D.S.; Fingolimod protects against ischemic white matter damage by modulating microglia toward M2 polarization via STAT3 pathway. Stroke 2017,48(12),3336-3346","journal-title":"Stroke"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pharmthera.2007.08.005","volume":"117","author":"Dev K.K.","year":"2008","unstructured":"Dev K.K.; Mullershausen F.; Mattes H.; Kuhn R.R.; Bilbe G.; Hoyer D.; Mir A.; Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 2008,117(1),77-93","journal-title":"Pharmacol Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1046\/j.1471-4159.2003.02219.x","volume":"88","author":"Harada J.","year":"2004","unstructured":"Harada J.; Foley M.; Moskowitz M.A.; Waeber C.; Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem 2004,88(4),1026-1039","journal-title":"J Neurochem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jns.2008.06.031","volume":"274","author":"Miron V.E.","year":"2008","unstructured":"Miron V.E.; Schubart A.; Antel J.P.; Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 2008,274(1-2),13-17","journal-title":"J Neurol Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.brainresbull.2016.04.004","volume":"124","author":"Nazari M.","year":"2016","unstructured":"Nazari M.; Keshavarz S.; Rafati A.; Namavar M.R.; Haghani M.; Fingolimod (FTY720) improves hippocampal synaptic plasticity and memory deficit in rats following focal cerebral ischemia. Brain Res Bull 2016,124,95-102","journal-title":"Brain Res Bull"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1152\/physrev.00030.2009","volume":"90","author":"Ravikumar B.","year":"2010","unstructured":"Ravikumar B.; Sarkar S.; Davies J.E.; Futter M.; Garcia-Arencibia M.; Green-Thompson Z.W.; Jimenez-Sanchez M.; Korolchuk V.I.; Lichtenberg M.; Luo S.; Massey D.C.; Menzies F.M.; Moreau K.; Narayanan U.; Renna M.; Siddiqi F.H.; Underwood B.R.; Winslow A.R.; Rubinsztein D.C.; Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev 2010,90(4),1383-1435","journal-title":"Physiol Rev"},{"key":"ref=63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188748","volume":"12","author":"Li X.","year":"2017","unstructured":"Li X.; Wang M.H.; Qin C.; Fan W.H.; Tian D.S.; Liu J.L.; Fingolimod suppresses neuronal autophagy through the mTOR\/p70S6K pathway and alleviates ischemic brain damage in mice. PLoS One 2017,12(11)","journal-title":"PLoS One"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"762","DOI":"10.4161\/auto.6412","volume":"4","author":"Wen Y.D.","year":"2008","unstructured":"Wen Y.D.; Sheng R.; Zhang L.S.; Han R.; Zhang X.; Zhang X.D.; Han F.; Fukunaga K.; Qin Z.H.; Neuronal injury in rat model of permanent focal cerebral ischemia is associated with activation of autophagic and lysosomal pathways. Autophagy 2008,4(6),762-769","journal-title":"Autophagy"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"Laplante M.","year":"2012","unstructured":"Laplante M.; Sabatini D.M.; mTOR signaling in growth control and disease. Cell 2012,149(2),274-293","journal-title":"Cell"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/glia.23536","volume":"67","author":"Rajan W.D.","year":"2019","unstructured":"Rajan W.D.; Wojtas B.; Gielniewski B.; Gieryng A.; Zawadzka M.; Kaminska B.; Dissecting functional phenotypes of microglia and macrophages in the rat brain after transient cerebral ischemia. Glia 2019,67(2),232-245","journal-title":"Glia"},{"key":"ref=67","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7584621","volume":"2017","author":"M\u00fcller J.","year":"2017","unstructured":"M\u00fcller J.; von Bernstorff W.; Heidecke C.D.; Schulze T.; Differential S1P receptor profiles on M1- and M2-polarized macrophages affect macrophage cytokine production and migration. BioMed Res Int 2017,2017","journal-title":"BioMed Res Int"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1016\/j.cellsig.2014.07.009","volume":"26","author":"Park S.J.","year":"2014","unstructured":"Park S.J.; Lee K.P.; Kang S.; Lee J.; Sato K.; Chung H.Y.; Okajima F.; Im D.S.; Sphingosine 1-phosphate induced anti-atherogenic and atheroprotective M2 macrophage polarization through IL-4. Cell Signal 2014,26(10),2249-2258","journal-title":"Cell Signal"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1161\/CIRCRESAHA.107.170779","volume":"102","author":"Hughes J.E.","year":"2008","unstructured":"Hughes J.E.; Srinivasan S.; Lynch K.R.; Proia R.L.; Ferdek P.; Hedrick C.C.; Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res 2008,102(8),950-958","journal-title":"Circ Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1096\/fj.201600788RR","volume":"32","author":"Zhao S.","year":"2018","unstructured":"Zhao S.; Adebiyi M.G.; Zhang Y.; Couturier J.P.; Fan X.; Zhang H.; Kellems R.E.; Lewis D.E.; Xia Y.; Sphingosine-1-phosphate receptor 1 mediates elevated IL-6 signaling to promote chronic inflammation and multitissue damage in sickle cell disease. FASEB J 2018,32(5),2855-2865","journal-title":"FASEB J"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","volume":"22","author":"Maceyka M.","year":"2012","unstructured":"Maceyka M.; Harikumar K.B.; Milstien S.; Spiegel S.; Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012,22(1),50-60","journal-title":"Trends Cell Biol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa052643","volume":"355","author":"Kappos L.","year":"2006","unstructured":"Kappos L.; Antel J.; Comi G.; Montalban X.; O\u2019Connor P.; Polman C.H.; Haas T.; Korn A.A.; Karlsson G.; Radue E.W.; Group F.D.S.; Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006,355(11),1124-1140","journal-title":"N Engl J Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nn.3728","volume":"17","author":"Hait N.C.","year":"2014","unstructured":"Hait N.C.; Wise L.E.; Allegood J.C.; O\u2019Brien M.; Avni D.; Reeves T.M.; Knapp P.E.; Lu J.; Luo C.; Miles M.F.; Milstien S.; Lichtman A.H.; Spiegel S.; Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci 2014,17(7),971-980","journal-title":"Nat Neurosci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1535-7163.MCT-13-0150","volume":"13","author":"Crist\u00f3bal I.","year":"2014","unstructured":"Crist\u00f3bal I.; Manso R.; Rinc\u00f3n R.; Caram\u00e9s C.; Senin C.; Borrero A.; Mart\u00ednez-Useros J.; Rodriguez M.; Zazo S.; Aguilera O.; Madoz-G\u00farpide J.; Rojo F.; Garc\u00eda-Foncillas J.; PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther 2014,13(4),938-947","journal-title":"Mol Cancer Ther"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1161\/STROKEAHA.109.552554","volume":"40","author":"Saver J.L.","year":"2009","unstructured":"Saver J.L.; Albers G.W.; Dunn B.; Johnston K.C.; Fisher M.; Consortium S.V.; Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke 2009,40(7),2594-2600","journal-title":"Stroke"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1161\/STROKEAHA.109.560714","volume":"40","author":"Wacker B.K.","year":"2009","unstructured":"Wacker B.K.; Park T.S.; Gidday J.M.; Hypoxic preconditioning-induced cerebral ischemic tolerance: role of microvascular sphingosine kinase 2. Stroke 2009,40(10),3342-3348","journal-title":"Stroke"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/nm.1999","volume":"15","author":"Shichita T.","year":"2009","unstructured":"Shichita T.; Sugiyama Y.; Ooboshi H.; Sugimori H.; Nakagawa R.; Takada I.; Iwaki T.; Okada Y.; Iida M.; Cua D.J.; Iwakura Y.; Yoshimura A.; Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med 2009,15(8),946-950","journal-title":"Nat Med"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/jnc.13946","volume":"140","author":"Rolland W.B.","year":"2017","unstructured":"Rolland W.B.; Krafft P.R.; Lekic T.; Klebe D.; LeGrand J.; Weldon A.J.; Xu L.; Zhang J.H.; Fingolimod confers neuroprotection through activation of Rac1 after experimental germinal matrix hemorrhage in rat pups. J Neurochem 2017,140(5),776-786","journal-title":"J Neurochem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.expneurol.2012.12.009","volume":"241","author":"Rolland W.B.","year":"2013","unstructured":"Rolland W.B.; Lekic T.; Krafft P.R.; Hasegawa Y.; Altay O.; Hartman R.; Ostrowski R.; Manaenko A.; Tang J.; Zhang J.H.; Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Exp Neurol 2013,241,45-55","journal-title":"Exp Neurol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12974-015-0234-7","volume":"12","author":"Xu H.L.","year":"2015","unstructured":"Xu H.L.; Pelligrino D.A.; Paisansathan C.; Testai F.D.; Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage. J Neuroinflammation 2015,12,16","journal-title":"J Neuroinflammation"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.016371","volume":"132","author":"Zhu Z.","year":"2015","unstructured":"Zhu Z.; Fu Y.; Tian D.; Sun N.; Han W.; Chang G.; Dong Y.; Xu X.; Liu Q.; Huang D.; Shi F.D.; Combination of the Immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation 2015,132(12),1104-1112","journal-title":"Circulation"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/1352458515587753","volume":"22","author":"Racca V.","year":"2016","unstructured":"Racca V.; Di Rienzo M.; Cavarretta R.; Toccafondi A.; Vaini E.; Ferratini M.; Rovaris M.; Fingolimod effects on left ventricular function in multiple sclerosis. Mult Scler 2016,22(2),201-211","journal-title":"Mult Scler"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1212\/WNL.0000000000000137","volume":"82","year":"2014","unstructured":"Karlsson, G.; Francis, G.; Koren, G.; Heining, P.; Zhang, X.; Cohen, J.A.; Kappos, L.; Collins, W. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014,82(8),674-680","journal-title":"Neurology"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/170578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T14:44:38Z","timestamp":1695480278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/170578\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":83,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,6,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666190308133732","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}